GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel

Diabetes

Volumn 61, Issue 10, 2012, Pages 2585-2591

  Calabria, Andrew C ^a   Li, Changhong ^a,b   Gallagher, Paul R ^a   Stanley, Charles A ^a,b   De León, Diva D ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; AMINO ACID; EXENDIN 9 39; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG MEGADOSE; FEMALE; GENE MUTATION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PANCREAS ISLET CELL; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CONGENITAL HYPERINSULINISM; CROSS-OVER STUDIES; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFANT, NEWBORN; INSULIN; ISLETS OF LANGERHANS; KATP CHANNELS; MALE; MUTATION; PEPTIDE FRAGMENTS; PILOT PROJECTS; RECEPTORS, GLUCAGON;

EID: 84866607794     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0166     Document Type: Article

References (30)

1. Stanley CA. Advances in diagnosis and treatment of hyperinsulinism in infants and children. J Clin Endocrinol Metab 2002;87:4857-4859 (Pubitemid 35316315)
2. Beltrand J, Caquard M, Arnoux JB, et al. Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care 2012;35:198-203
3. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009;122 (Suppl.):S3-S10
4. D'Alessio DA, Vogel R, Prigeon R, et al. Elimination of the action of glucagon- like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 1996;97:133-138 (Pubitemid 26021703)
5. Edwards CM, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48:86-93 (Pubitemid 29019356)
6. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006;55:243-251 (Pubitemid 43117285)
7. De León DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 2003;52:365-371 (Pubitemid 36173191)
8. Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 2005;128: 125-134 (Pubitemid 40380913)
9. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Goke B. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 2009;21:609-618
10. Nicolaus M, Brödl J, Linke R, Woerle HJ, Göke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 2011;96:229-236
11. Palladino AA, Sayed S, Katz LE, Gallagher PR, De León DD. Increased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplication. J Clin Endocrinol Metab 2009;94:39-44
12. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin(9- 39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998;101:1421-1430 (Pubitemid 28166840)
13. De León DD, Li C, Delson MI, Matschinsky FM, Stanley CA, Stoffers DA. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion. J Biol Chem 2008;283:25786-25793
14. Li C, Buettger C, Kwagh J, et al. A signaling role of glutamine in insulin secretion. J Biol Chem 2004;279:13393-13401 (Pubitemid 38468862)
15. Rickels MR, Naji A. Reactive hypoglycaemia following GLP-1 infusion in pancreas transplant recipients. Diabetes Obes Metab 2010;12:731-733
16. Toft-Nielsen M, Madsbad S, Holst JJ. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 1998;41:1180-1186 (Pubitemid 28449084)
17. Todd JF, Stanley SA, Roufosse CA, et al. A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes. Lancet 2003;361:228-230 (Pubitemid 36126227)
18. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091 (Pubitemid 40616617)
19. Reimann F, Gribble FM. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002;51:2757-2763 (Pubitemid 34970929)
20. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011;60:2308-2314
21. Serre V, Dolci W, Schaerer E, et al. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence. Endocrinology 1998;139:4448-4454 (Pubitemid 28487758)
22. Flamez D, Gilon P, Moens K, et al. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 1999;48:1979-1986 (Pubitemid 29458360)
23. Moens K, Flamez D, Van Schravendijk C, Ling Z, Pipeleers D, Schuit F. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors. Diabetes 1998;47:66-72 (Pubitemid 28030809)
24. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 1994;43:104-108 (Pubitemid 24047112)
25. Van Dijk G, Lindskog S, Holst JJ, Steffens AB, Ahrén B. Effects of glucagon-like peptide-I on glucose turnover in rats. Am J Physiol 1996;270:E1015-E1021
26. Hussain K, Bryan J, Christesen HT, Brusgaard K, Aguilar-Bryan L. Serum glucagon counterregulatory hormonal response to hypoglycemia is blunted in congenital hyperinsulinism. Diabetes 2005;54:2946-2951 (Pubitemid 41401091)
27. Gromada J, Ma X, Høy M, et al. ATP-sensitive K+ channel-dependent regulation of glucagon release and electrical activity by glucose in wild-type and SUR1-/- mouse alpha-cells. Diabetes 2004;53(Suppl. 3):S181-S189 (Pubitemid 39564542)
28. Shiota C, Rocheleau JV, Shiota M, Piston DW, Magnuson MA. Impaired glucagon secretory responses in mice lacking the type 1 sulfonylurea receptor. Am J Physiol Endocrinol Metab 2005;289:E570-E577 (Pubitemid 41356077)
29. Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA. Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993;123:637-643 (Pubitemid 23287542)
30. Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes 2010;11:142-147